ArticleJournal of primary care & community health
An Intersectional Analysis of Social Deprivation and Patient Characteristics on Nirmatrelvir-Ritonavir for Treatment of COVID-19 in U.S. Primary Care Practices, 2021 to 2023.
Article in Journal of primary care & community health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveCalculate rates of nirmatrelvir-ritonavir prescription and assess area-level social deprivation as an effect modifier of patient characteristics on nirmatrelvir-ritonavir for the treatment of COVID-19.
methodsRetrospective cohort study December 22, 2021 to June 30, 2023 using electronic health record (EHR) data of primary care patients from the American Family Cohort (AFC). Eligible patients had documented COVID-19 between December 15, 2021 and February 28, 2023; ≥1 healthcare encounter between January 1, 2020 and December 14, 2021; and ≥1 healthcare encounter between December 15, 2021 and June 30, 2023. Of the 3 678 474 AFC patients observed during the study period, 86 043 met inclusion criteria. Social deprivation was measured by census tract of patient residence using 2020 Social Deprivation Index (SDI) values; quintiles were calculated using national census tract distribution with lower values indicating less deprivation. The primary statistical analysis estimated the probability of nirmatrelvir-ritonavir prescription using logistic regression. The secondary analysis assessed area-level social deprivation as an effect modifier of patient characteristics on nirmatrelvir-ritonavir prescribing.
resultsOf the cohort, 26 797 (31.1%) patients were prescribed nirmatrelvir-ritonavir. Asian patients were more likely than White patients to receive a nirmatrelvir-ritonavir prescription in the lowest 2 quintiles of social deprivation (Q1: OR = 1.33 (95% CI = 1.10, 1.59); Q2: OR = 1.29 (95% CI = 1.02, 1.61)). Non-Hispanic/Latino patients in the lowest quintile had 1.32 times the odds of nirmatrelvir-ritonavir prescribing (95% CI = 1.12, 1.56) compared to Hispanic/Latino patients; however, in the third, fourth, and fifth quintiles, non-Hispanic/Latino patients had a reduced odds of a nirmatrelvir-ritonavir prescription compared to Hispanic/Latino patients (Q3: OR = 0.83 (95% CI = 0.73, 0.95); Q4: OR = 0.67 (95% CI = 0.60, 0.75); Q5: OR = 0.67 (95% CI = 0.56, 0.80)).
conclusionsOur research suggests intersectionality between patient race/ethnicity with economic status - with meaningful implications for understanding access to new medications within primary care, as they relate to treatment for communicable diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.